IVI partners with QuadMedicine to develop microneedle-based vaccines
Dr. Jerome Kim (left), General Director of IVI and Mr. Seung-Ki Baek, CEO of QuadMedicine
June 17, 2019 – SEOUL, South Korea. Today IVI exchanged a memorandum of understanding with QuadMedicine, a Korea-based biotech venture, to collaborate on the development of microneedle-based vaccines. With expertise in microneedles and research, QuadMedicine is an important partner to IVI – working to transform the way in which people get vaccinated and sharing IVI’s mandate of making vaccines more accessible and affordable.
Under this agreement, IVI will provide vaccines and technology to the company. IVI will also conduct an evaluation of the stability of microneedle-based vaccines, which will be developed by QuadMedicine for IVI. By setting up an innovative, low-cost production process, QuadMedicine will aim to develop safe, effective and affordable vaccines.
IVI is looking forward to working together and further developing a fruitful partnership.
From left to right: Dr. Manki Song, Acting Deputy Director General, Science of IVI; Dr. Jerome Kim, General Director of IVI; Mr. Seung-Ki Baek, CEO of QuadMedicine; Prof. Jung-Hwan Park, Skin Engineering Lab at Gachon University; Prof. Jae-Myun Lee of Yonsei University of College of Medicine.
Members of the Vi-DT team at Kanti Children's Hospital in Kathmandu, Nepal.